ORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates

Posted: May 9, 2023 at 12:10 am

Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer

Read more:
ORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates

Related Posts